MiMedx price target raised to $14 from $13 at Mizuho

Mizuho raised the firm’s price target on MiMedx to $14 from $13 and keeps a Buy rating on the shares. The company reported a solid Q4 beat, driven by acceleration in core Woundcare and Surgical, share shift toward EpiFix in the physician office setting, and new-product contribution, which also aided gross margin outperformance, the analyst tells investors in a research note.